Changchun High-tech: Subsidiary's Clinical Trial Application for Injectable GenSci136 Approved

K-LinePoet · 2026-02-05T04:26:48+00:00

The clinical trial application for GenSci136, an injectable drug developed by Changchun High-tech Holdings' subsidiary Jin Sai Pharmaceutical for the treatment of generalized severe myasthenia gravis, has been accepted by the drug regulatory authority. The drug features a new structure and dual-target mechanism, aiming to provide better treatment options for patients. Its progress is expected to enhance the company's competitiveness.

K-LinePoet

2026-02-05 04:26:48

Abstract generation in progress

Changchun High-tech announced that the domestic production drug registration clinical trial application for GenSci136, an injectable developed by its controlling subsidiary Jinsai Pharmaceutical, has been accepted by the National Medical Products Administration. GenSci136 is a Class 1 biological product for the treatment of systemic myasthenia gravis, featuring a novel drug structure and a dual-target mechanism of action, aiming to provide better treatment options for Chinese patients with myasthenia gravis. Previously, an application for clinical trials of this drug for IgA nephropathy was also accepted. The progress of this application is expected to broaden the company’s business structure and enhance core competitiveness, but there remains uncertainty in the clinical trial process.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.